Please try another search
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Martine A. Rothblatt | 68 | 1996 | Founder, Chairman & CEO |
Christopher Causey | 60 | 2003 | Independent Director |
Raymond A. Dwek | 81 | 2002 | Independent Director & Member of the Scientific Advisory Board |
Christopher Patusky | 59 | 2002 | Independent Vice Chairman & Lead Independent Director |
Louis W. Sullivan | 90 | 2002 | Independent Director & Member of the Scientific Advisory Board |
Raymond C. Kurzweil | 75 | 2002 | Independent Director |
Thomas G. Thompson | 81 | 2010 | Independent Director |
Magdi H. Yacoub | 87 | - | Member of the Scientific Advisory Board |
Richard Giltner | 59 | 2009 | Independent Director |
Samuel O. Thier | 86 | - | Member of the Scientific Advisory Board |
Nilda Mesa | 64 | 2018 | Independent Director |
Judy D. Olian | 72 | 2015 | Independent Director |
Mardi Gomberg-Maitland | - | - | Member of the Scientific Advisory Board |
Robert C. Bourge | - | - | Member of the Scientific Advisory Board |
Jan K. Malcolm | - | 2024 | Independent Director |
Linda Maxwell | 49 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review